Tisagenlecleucel and Lisocabtagene Maraleucel: Comparative Efficacy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：0

作者：

Schuster, Stephen J. ^{[1
]}

Zhang, Jie ^{[2
]}

Yang, Hongbo ^{[3
]}

Agarwal, Abhijit ^{[2
]}

Tang, Wenxi ^{[3
]}

Prieto, Marcela Martinez ^{[2
]}

Bollu, Vamsi ^{[2
]}

Kuzan, David ^{[2
]}

Maziarz, Richard ^{[4
]}

Kersten, Marie Jose ^{[5
]}

机构：

[1] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA

[2] Novartis Pharmaceut, E Hanover, NJ USA

[3] Anal Grp Inc, Boston, MA USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

关键词：

ABCL; diffuse large B-cell lymphoma; CAR-T cell therapy; MAIC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-166

引用

页码：S380 / S381

页数：2